Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients

June 4, 2017 updated by: Jing Li
This study evaluated the association between HMGB1 and diastolic dysfunction in hypertensive patients. HMGB1 level were tested in all patients, and diastolic function determined by echocardiographic.

Study Overview

Status

Unknown

Study Type

Observational

Enrollment (Anticipated)

100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The study sample is recruited from the patients examined in the physical examination center of our hospital.

Description

Inclusion Criteria:

All of the hypertensive patients in both diastolic dysfunction and control groups were either newly diagnosed or were aware of hypertension without using any pharmacotherapy.

-

Exclusion Criteria:

Individuals already under treatment for hypertension were not include.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences of HMGB1 levels between hypertensive patients with and without diastolic dysfunction
Time Frame: on the day of admission
Blood samples of all individuals are collected on the day of admission and HMGB1 levels are tested. Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.
on the day of admission

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences of HMGB1 levels between grades of diastolic dysfunction
Time Frame: on the day of admission
Blood samples of all individuals are collected on the day of admission and HMGB1 levels are tested. Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.
on the day of admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 15, 2017

Primary Completion (Anticipated)

December 31, 2017

Study Completion (Anticipated)

December 31, 2017

Study Registration Dates

First Submitted

April 16, 2017

First Submitted That Met QC Criteria

June 4, 2017

First Posted (Actual)

June 6, 2017

Study Record Updates

Last Update Posted (Actual)

June 6, 2017

Last Update Submitted That Met QC Criteria

June 4, 2017

Last Verified

June 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 2017032901

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation

Subscribe